Alzheimer's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You can be male or female, of any race
- You must be over 18 years old
- You must already be taking part in a related research project connected to the Knight Alzheimer's Disease Research Center at Washington University, and be referred by their team and a Washington University doctor
- You must have either normal thinking and memory abilities, or be in the early stages of Alzheimer's disease symptoms
- You must be willing and able to take part in all study procedures
- You must be able to understand and agree to the study on your own, and be able to follow the study instructions
Who may not be able to join:
- You have a health condition that the study doctor believes could put you at risk, make it hard to complete the study procedures, or affect the study results (for example, severe back pain that would prevent you from lying still during scans)
- You have had an allergic reaction to either of the imaging agents used in this study, called AV-1451 (Flortaucipir) or PIB
- You have a reason why you cannot safely have a PET scan, CT scan, or MRI — for example, having certain electronic medical devices in your body, or being unable to lie still for long periods
- You experience severe claustrophobia (extreme fear of enclosed spaces)
- You are currently pregnant or breastfeeding; women must also agree to avoid becoming pregnant and to either avoid sexual activity or use reliable contraception for 24 hours after receiving the Flortaucipir injection
- You have taken part in a clinical trial involving a study drug or device in the 30 days before joining this study
- You plan to join another drug or device study before this study is completed
- You have taken part in other research studies involving radioactive materials in the past 12 months, where the combined radiation exposure would exceed the limits set by U.S. federal regulations (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Tammie Benzinger, MD, PhD, Washington University School of Medicine
Phone: 314-362-1558
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
AD Biomarkers seen on Amyloid PET at Baseline and Years 1, 2, and/or 3; AD Biomarkers seen on Tau PET at Baseline and Years 1, 2, and/or 3; AD Biomarkers seen on MRI at Baseline and Years 1, 2, and/or 3; Compare and Correlate Predictive Ability of Biomarkers Seen with Different Imaging Variables for Onset of Symptoms
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.